In May 2023, the U.S. Food and Drug Administration (FDA) announced it had granted accelerated approval for the first CD20 bispecific antibody drug, epcoritamab-bysp (Epkinly^™) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In June 2024, the FDA expanded the indication with accelerated approval for the treatment of relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

One potential positive from the COVID-19 pandemic was heightened awareness and use of personal protective equipment (PPE). However, protecting people from virus transmission does not automatically equate to protecting surfaces from hazardous drugs, researchers reported in the August 2024 issue of the Clinical Journal of Oncology Nursing. Although surface contamination varied by agent and setting, overall, they found no significant change from pre- to post-pandemic.

If you’re interested in identifying best practices and finding new and better ways to support patient care, scientific study and clinical research need nurses to serve in a variety of roles, including PhDs, DNPs, nurse researchers, and direct-care clinical nurses. In fact, all nursing roles contribute to the research cycle, speakers said during a 2024 ONS Congress^® session about the integration of and collaboration between nursing researcher roles.

Mrs. Brown (she/her) is a 70-year-old assigned female at birth with a history of diffuse large B-cell lymphoma with central nervous system involvement. She received axicabtagene ciloleucel and tolerated the immune effector cell infusion.

A mainstay of many cancer treatments for decades, 5-fluorouracil injection package inserts were updated in March 2024 through the U.S. Food and Drug Administration’s Project Renewal. The revisions add pharmacogenomics information and a safety warning about severe adverse reactions in patients with DPD deficiency.